Does the media refer more to ELAN or ONC?

In the previous week, Elanco Animal Health had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Elanco Animal Health and 14 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.62 beat Elanco Animal Health's score of 0.48 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RPRX or ELAN?

In the previous week, Royalty Pharma and Royalty Pharma both had 17 articles in the media. Royalty Pharma's average media sentiment score of 0.98 beat Elanco Animal Health's score of 0.48 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ELAN or ZTS?

In the previous week, Elanco Animal Health had 1 more articles in the media than Zoetis. MarketBeat recorded 17 mentions for Elanco Animal Health and 16 mentions for Zoetis. Zoetis' average media sentiment score of 0.62 beat Elanco Animal Health's score of 0.48 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zoetis 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ELAN or VTRS?

In the previous week, Elanco Animal Health had 11 more articles in the media than Viatris. MarketBeat recorded 17 mentions for Elanco Animal Health and 6 mentions for Viatris. Viatris' average media sentiment score of 0.64 beat Elanco Animal Health's score of 0.48 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELAN or NBIX?

In the previous week, Elanco Animal Health had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 17 mentions for Elanco Animal Health and 14 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.83 beat Elanco Animal Health's score of 0.48 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neurocrine Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Elanco Animal Health (ELAN) Competitors

$26.80 +0.30 (+1.13%)

Closing price 11/13/2026 03:59 PM Eastern

Extended Trading

$26.77 -0.03 (-0.10%)

As of 11/13/2026 07:57 PM Eastern

Compare

ELAN vs. ONC, RPRX, ZTS, VTRS, and NBIX

Should you buy Elanco Animal Health stock or one of its competitors? Elanco Animal Health's main competitors and comparable companies include BeOne Medicines (ONC), Royalty Pharma (RPRX), Zoetis (ZTS), Viatris (VTRS), and Neurocrine Biosciences (NBIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Elanco Animal Health compare to BeOne Medicines?

Elanco Animal Health (NYSE:ELAN) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Elanco Animal Health has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Elanco Animal Health currently has a consensus price target of $29.75, suggesting a potential upside of 11.01%. BeOne Medicines has a consensus price target of $440.57, suggesting a potential upside of 5.77%. Given Elanco Animal Health's higher probable upside, equities analysts plainly believe Elanco Animal Health is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
BeOne Medicines	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00

BeOne Medicines has a net margin of 13.86% compared to Elanco Animal Health's net margin of -2.86%. BeOne Medicines' return on equity of 19.04% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-2.86%	8.80%	4.32%
BeOne Medicines	13.86%	19.04%	10.70%

In the previous week, Elanco Animal Health had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Elanco Animal Health and 14 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.62 beat Elanco Animal Health's score of 0.48 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BeOne Medicines has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.84	-$232M	-$0.30	N/A
BeOne Medicines	$5.34B	8.56	$286.93M	$7.87	52.93

Summary

BeOne Medicines beats Elanco Animal Health on 12 of the 16 factors compared between the two stocks.

How does Elanco Animal Health compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Elanco Animal Health (NYSE:ELAN) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Royalty Pharma presently has a consensus price target of $63.29, suggesting a potential downside of 8.69%. Elanco Animal Health has a consensus price target of $29.75, suggesting a potential upside of 11.01%. Given Elanco Animal Health's higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Royalty Pharma and Royalty Pharma both had 17 articles in the media. Royalty Pharma's average media sentiment score of 0.98 beat Elanco Animal Health's score of 0.48 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Royalty Pharma has a net margin of 25.68% compared to Elanco Animal Health's net margin of -2.86%. Royalty Pharma's return on equity of 30.04% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	25.68%	30.04%	14.97%
Elanco Animal Health	-2.86%	8.80%	4.32%

Royalty Pharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

Royalty Pharma has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	16.76	$770.95M	$1.20	57.76
Elanco Animal Health	$4.72B	2.84	-$232M	-$0.30	N/A

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Royalty Pharma beats Elanco Animal Health on 10 of the 15 factors compared between the two stocks.

How does Elanco Animal Health compare to Zoetis?

Elanco Animal Health (NYSE:ELAN) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Elanco Animal Health had 1 more articles in the media than Zoetis. MarketBeat recorded 17 mentions for Elanco Animal Health and 16 mentions for Zoetis. Zoetis' average media sentiment score of 0.62 beat Elanco Animal Health's score of 0.48 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zoetis	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Zoetis has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.84	-$232M	-$0.30	N/A
Zoetis	$9.47B	3.59	$2.67B	$5.88	14.23

Zoetis has a net margin of 26.15% compared to Elanco Animal Health's net margin of -2.86%. Zoetis' return on equity of 85.90% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-2.86%	8.80%	4.32%
Zoetis	26.15%	85.90%	18.39%

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Elanco Animal Health has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market. Comparatively, Zoetis has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Elanco Animal Health currently has a consensus target price of $29.75, indicating a potential upside of 11.01%. Zoetis has a consensus target price of $101.25, indicating a potential upside of 21.04%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Zoetis	1 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Zoetis beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.

How does Elanco Animal Health compare to Viatris?

Elanco Animal Health (NYSE:ELAN) and Viatris (NASDAQ:VTRS) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Elanco Animal Health has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market. Comparatively, Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

In the previous week, Elanco Animal Health had 11 more articles in the media than Viatris. MarketBeat recorded 17 mentions for Elanco Animal Health and 6 mentions for Viatris. Viatris' average media sentiment score of 0.64 beat Elanco Animal Health's score of 0.48 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health currently has a consensus price target of $29.75, suggesting a potential upside of 11.01%. Viatris has a consensus price target of $21.11, suggesting a potential upside of 1.40%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, research analysts plainly believe Elanco Animal Health is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Viatris	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Elanco Animal Health has higher earnings, but lower revenue than Viatris. Elanco Animal Health is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.84	-$232M	-$0.30	N/A
Viatris	$14.30B	1.67	-$3.51B	-$0.53	N/A

Elanco Animal Health has a net margin of -2.86% compared to Viatris' net margin of -4.13%. Viatris' return on equity of 20.82% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-2.86%	8.80%	4.32%
Viatris	-4.13%	20.82%	8.30%

Summary

Elanco Animal Health beats Viatris on 12 of the 17 factors compared between the two stocks.

How does Elanco Animal Health compare to Neurocrine Biosciences?

Elanco Animal Health (NYSE:ELAN) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Elanco Animal Health has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

In the previous week, Elanco Animal Health had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 17 mentions for Elanco Animal Health and 14 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.83 beat Elanco Animal Health's score of 0.48 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurocrine Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health presently has a consensus price target of $29.75, suggesting a potential upside of 11.01%. Neurocrine Biosciences has a consensus price target of $202.59, suggesting a potential upside of 21.02%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Neurocrine Biosciences has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.84	-$232M	-$0.30	N/A
Neurocrine Biosciences	$2.86B	5.92	$478.60M	$6.74	24.84

Neurocrine Biosciences has a net margin of 18.98% compared to Elanco Animal Health's net margin of -2.86%. Neurocrine Biosciences' return on equity of 23.39% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-2.86%	8.80%	4.32%
Neurocrine Biosciences	18.98%	23.39%	16.22%

Summary

Neurocrine Biosciences beats Elanco Animal Health on 12 of the 16 factors compared between the two stocks.

Get Elanco Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELAN vs. The Competition

Export

Metric	Elanco Animal Health	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$13.25B	$13.77B	$7.84B	$23.48B
Dividend Yield	N/A	2.56%	2.46%	3.78%
P/E Ratio	-89.33	29.40	34.71	27.05
Price / Sales	2.84	7.34	8.66	3.38
Price / Cash	11.42	15.74	21.93	15.51
Price / Book	2.02	4.93	4.35	3.72
Net Income	-$232M	$2.88B	$3.51B	$1.08B
7 Day Performance	4.50%	-0.21%	-1.49%	0.58%
1 Month Performance	19.07%	-3.25%	-2.55%	1.11%
1 Year Performance	27.10%	-6.14%	0.92%	7.21%

Elanco Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELAN Elanco Animal Health	3.1026 of 5 stars	$26.80 +1.1%	$29.75 +11.0%	+21.8%	$13.25B	$4.72B	N/A	9,400	Earnings Report Gap Up
ONC BeOne Medicines	3.6787 of 5 stars	$361.27 -2.4%	$412.26 +14.1%	+13.1%	$40.66B	$6.13B	63.60	12,000	Analyst Forecast Insider Trade
RPRX Royalty Pharma	3.6401 of 5 stars	$66.52 -1.0%	$61.57 -7.4%	+74.5%	$37.27B	$2.38B	45.88	100	Positive News Analyst Upgrade
ZTS Zoetis	4.5984 of 5 stars	$83.18 +4.3%	$93.79 +12.7%	-30.9%	$32.15B	$9.47B	13.70	14,500
VTRS Viatris	2.7283 of 5 stars	$18.67 -1.9%	$20.88 +11.8%	+90.8%	$21.86B	$14.74B	N/A	30,000	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ELAN) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elanco Animal Health (ELAN) Competitors

ELAN vs. ONC, RPRX, ZTS, VTRS, and NBIX

How does Elanco Animal Health compare to BeOne Medicines?

Summary

How does Elanco Animal Health compare to Royalty Pharma?

Summary

How does Elanco Animal Health compare to Zoetis?

Summary

How does Elanco Animal Health compare to Viatris?

Summary

How does Elanco Animal Health compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAN vs. The Competition

Elanco Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elanco Animal Health (ELAN) Competitors

ELAN vs. ONC, RPRX, ZTS, VTRS, and NBIX

How does Elanco Animal Health compare to BeOne Medicines?

Which has more risk & volatility, ELAN or ONC?

Do analysts recommend ELAN or ONC?

Is ELAN or ONC more profitable?

Does the media refer more to ELAN or ONC?

Do insiders and institutionals have more ownership in ELAN or ONC?

Which has higher valuation & earnings, ELAN or ONC?

Summary

How does Elanco Animal Health compare to Royalty Pharma?

Do analysts rate RPRX or ELAN?

Does the media prefer RPRX or ELAN?

Is RPRX or ELAN more profitable?

Which has more volatility & risk, RPRX or ELAN?

Which has better valuation & earnings, RPRX or ELAN?

Do institutionals and insiders hold more shares of RPRX or ELAN?

Summary

How does Elanco Animal Health compare to Zoetis?

Does the media refer more to ELAN or ZTS?

Which has stronger earnings and valuation, ELAN or ZTS?

Is ELAN or ZTS more profitable?

Do insiders and institutionals believe in ELAN or ZTS?

Which has more risk & volatility, ELAN or ZTS?

Do analysts recommend ELAN or ZTS?

Summary

How does Elanco Animal Health compare to Viatris?

Do insiders & institutionals believe in ELAN or VTRS?

Which has more volatility and risk, ELAN or VTRS?

Does the media refer more to ELAN or VTRS?

Do analysts rate ELAN or VTRS?

Which has better earnings & valuation, ELAN or VTRS?

Is ELAN or VTRS more profitable?

Summary

How does Elanco Animal Health compare to Neurocrine Biosciences?

Do institutionals and insiders hold more shares of ELAN or NBIX?

Which has more risk and volatility, ELAN or NBIX?

Does the media prefer ELAN or NBIX?

Do analysts prefer ELAN or NBIX?

Which has higher valuation & earnings, ELAN or NBIX?

Is ELAN or NBIX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAN vs. The Competition

Elanco Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools